-+ 0.00%
-+ 0.00%
-+ 0.00%

Esperion says Phase 2 trial shows bempedoic acid lowers LDL-C 6%-25% in children with familial hypercholesterolemia

PUBT·05/26/2026 12:01:44
Listen to the news
Esperion says Phase 2 trial shows bempedoic acid lowers LDL-C 6%-25% in children with familial hypercholesterolemia
  • Esperion outlined new bempedoic acid analyses already presented at the European Atherosclerosis Society Congress 2026 in Athens on May 24-27.
  • A Phase 2 pediatric study found the drug lowered LDL cholesterol in children with heterozygous familial hypercholesterolemia without new safety signals.
  • A separate CLEAR Outcomes post hoc analysis linked stronger LDL cholesterol responses in statin-intolerant adults to patient characteristics, including baseline ezetimibe use.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260800PRIMZONEFULLFEED9724117) on May 26, 2026, and is solely responsible for the information contained therein.